Achieve Life Sciences - A Long Report
Achieve has an excellent smoking cessation drug that has gone through phase 3 trials. A delay in filing its new drug application with the FDA has created a buying opportunity for investors.
Achieve Life Sciences (ACHV) went public via a shell company in 2017 to commercialize the smoking cessation drug Cytisinicline. Cytisinicline is derived from a plant-based compound and has a long history of use in Eastern Europe, but had not been tested in the U.S. Achieve’s central task is to usher the drug through clinical trials and the FDA approval process. Phase 3 trials are done. The company must complete a long-term safety trial before submitting the New Drug Application (NDA), likely a 1H25 event. I expect the company to be sold to a larger entity around the same time generating ~5x return for investors.
The attachment has the full report.
